Terms: = Lung cancer AND PCSK7, Q16549, 9159, ENSG00000160613, PC8, SPC7, PC7, LPC
66 results:
1. Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor.
Yu J; Xiong F; Xu Y; Xu H; Zhang X; Gao H; Li Y
Int Immunopharmacol; 2024 Jan; 127():111412. PubMed ID: 38160567
[TBL] [Abstract] [Full Text] [Related]
2. Modeling RET-Rearranged Non-Small Cell lung cancer (NSCLC): Generation of lung Progenitor Cells (lpcs) from Patient-Derived Induced Pluripotent Stem Cells (iPSCs).
Marcoux P; Hwang JW; Desterke C; Imeri J; Bennaceur-Griscelli A; Turhan AG
Cells; 2023 Dec; 12(24):. PubMed ID: 38132167
[TBL] [Abstract] [Full Text] [Related]
3. Lipidomics and pancreatic cancer risk in two prospective studies.
Naudin S; Sampson JN; Moore SC; Albanes D; Freedman ND; Weinstein SJ; Stolzenberg-Solomon R
Eur J Epidemiol; 2023 Jul; 38(7):783-793. PubMed ID: 37169992
[TBL] [Abstract] [Full Text] [Related]
4. Combined analysis of gut microbiome and serum metabolomics reveals novel biomarkers in patients with early-stage non-small cell lung cancer.
Ni B; Kong X; Yan Y; Fu B; Zhou F; Xu S
Front Cell Infect Microbiol; 2023; 13():1091825. PubMed ID: 36743312
[TBL] [Abstract] [Full Text] [Related]
5. Developing a primary tumor and lymph node 18F-FDG PET/CT-clinical (Tlpc) model to predict lymph node metastasis of resectable T2-4 NSCLC.
Wang M; Liu L; Dai Q; Jin M; Huang G
J Cancer Res Clin Oncol; 2023 Jan; 149(1):247-261. PubMed ID: 36565319
[TBL] [Abstract] [Full Text] [Related]
6. Assessment of plasma amino acids, purines, tricarboxylic acid cycle metabolites, and lipids levels in NSCLC patients based on LC-MS/MS quantification.
Cang S; Liu R; Mu K; Tang Q; Cui H; Bi K; Zhang Y; Li Q
J Pharm Biomed Anal; 2022 Nov; 221():114990. PubMed ID: 36208488
[TBL] [Abstract] [Full Text] [Related]
7. Plasma lipid-based machine learning models provides a potential diagnostic tool for colorectal cancer patients.
Yang C; Zhou S; Zhu J; Sheng H; Mao W; Fu Z; Chen Z
Clin Chim Acta; 2022 Nov; 536():191-199. PubMed ID: 36191612
[TBL] [Abstract] [Full Text] [Related]
8. Suppression of VEGFD expression by S-nitrosylation promotes the development of lung adenocarcinoma.
He Q; Qu M; Shen T; Xu Y; Luo J; Tan D; Xu C; Barkat MQ; Zeng LH; Wu X
J Exp Clin Cancer Res; 2022 Aug; 41(1):239. PubMed ID: 35941690
[TBL] [Abstract] [Full Text] [Related]
9. Non-Small Cell lung cancer Detection and Subtyping by UPLC-HRMS-Based Tissue Metabolomics.
Zang X; Zhang J; Jiao P; Xue X; Lv Z
J Proteome Res; 2022 Aug; 21(8):2011-2022. PubMed ID: 35856400
[TBL] [Abstract] [Full Text] [Related]
10. Activation of the Notch1-c-myc-VCAM1 signalling axis initiates liver progenitor cell-driven hepatocarcinogenesis and pulmonary metastasis.
Wu WR; Shi XD; Zhang FP; Zhu K; Zhang R; Yu XH; Qin YF; He SP; Fu HW; Zhang L; Zeng H; Zhu MS; Xu LB; Wong PP; Liu C
Oncogene; 2022 Apr; 41(16):2340-2356. PubMed ID: 35256782
[TBL] [Abstract] [Full Text] [Related]
11. Adaptive Lumpectomy Boost Planning Can Reduce Normal Tissue Exposure in Patients Receiving Hypofractionated Whole Breast Irradiation.
Sayan M; Yehia ZA; Jan I; Gupta A; Vergalasova I; Reviello M; Kumar S; Haffty B; Ohri N
Anticancer Res; 2022 Jan; 42(1):53-57. PubMed ID: 34969708
[TBL] [Abstract] [Full Text] [Related]
12. Mass spectrometry imaging revealed alterations of lipid metabolites in multicellular tumor spheroids in response to hydroxychloroquine.
Chen Y; Wang T; Xie P; Song Y; Wang J; Cai Z
Anal Chim Acta; 2021 Nov; 1184():339011. PubMed ID: 34625248
[TBL] [Abstract] [Full Text] [Related]
13. Highly sensitive detection of driver mutations from cytological samples and cfDNA in lung cancer.
Fujita K; Nakayama M; Sata M; Nagai Y; Hisata S; Mato N; Suzuki T; Bando M; Hizawa N; Hagiwara K
Cancer Med; 2021 Dec; 10(23):8595-8603. PubMed ID: 34617674
[TBL] [Abstract] [Full Text] [Related]
14. Screening and identification of potential novel lipid biomarkers for non-small cell lung cancer using ultra-high performance liquid chromatography tandem mass spectrometry.
Han YS; Shi LY; Chen JX; Chen J; Li ZB; Lu QQ; Zhang SQ; Liu J; Yi WJ; Jiang TT; Li JC; Huang J
Anat Rec (Hoboken); 2022 May; 305(5):1087-1099. PubMed ID: 34347376
[TBL] [Abstract] [Full Text] [Related]
15. Silencing PEX26 as an unconventional mode to kill drug-resistant cancer cells and forestall drug resistance.
Dahabieh MS; Huang F; Goncalves C; Flores González RE; Prabhu S; Bolt A; Di Pietro E; Khoury E; Heath J; Xu ZY; Rémy-Sarrazin J; Mann KK; Orthwein A; Boisvert FM; Braverman N; Miller WH; Del Rincón SV
Autophagy; 2022 Mar; 18(3):540-558. PubMed ID: 34074205
[TBL] [Abstract] [Full Text] [Related]
16. Argon plasma coagulation with atezolizumab and chemoradiation in lung pleomorphic cancer showed a remarkable response: Case report.
Harada M; Morikawa K; Kagoo N; Ito Y; Kubota T; Ichijo K; Mochizuki E; Uehara M; Matsuura S; Yasuda K; Tsukui M; Koshimizu N
Medicine (Baltimore); 2021 May; 100(21):e26149. PubMed ID: 34032770
[TBL] [Abstract] [Full Text] [Related]
17. Tumor-educated leukocytes mRNA as a diagnostic biomarker for non-small cell lung cancer.
Niu L; Guo W; Song X; Song X; Xie L
Thorac Cancer; 2021 Mar; 12(6):737-745. PubMed ID: 33474835
[TBL] [Abstract] [Full Text] [Related]
18. Intranasal delivery of cationic liposome-protamine complex mRNA vaccine elicits effective anti-tumor immunity.
Mai Y; Guo J; Zhao Y; Ma S; Hou Y; Yang J
Cell Immunol; 2020 Aug; 354():104143. PubMed ID: 32563850
[TBL] [Abstract] [Full Text] [Related]
19. Clinical significance of circulating tumor cells and metabolic signatures in lung cancer after surgical removal.
Yang D; Yang X; Li Y; Zhao P; Fu R; Ren T; Hu P; Wu Y; Yang H; Guo N
J Transl Med; 2020 Jun; 18(1):243. PubMed ID: 32552826
[TBL] [Abstract] [Full Text] [Related]
20. Metabolic and lipidomic characterization of malignant pleural effusion in human lung cancer.
Yang Z; Song Z; Chen Z; Guo Z; Jin H; Ding C; Hong Y; Cai Z
J Pharm Biomed Anal; 2020 Feb; 180():113069. PubMed ID: 31884394
[TBL] [Abstract] [Full Text] [Related]
[Next]
